224
Views
5
CrossRef citations to date
0
Altmetric
Review

Disturbance of inorganic phosphate metabolism in diabetes mellitus: clinical manifestations of phosphorus-depletion syndrome during recovery from diabetic ketoacidosis

&
Pages 319-324 | Published online: 27 Sep 2022

Abstract

The acute effects of intracellular phosphate depletion and hypophosphatemia on organs and tissues in and during recovery from diabetic ketoacidosis (DKA) have been reviewed. When insufficient phosphate and/or oxygen are available for high energy phosphate synthesis, cell homeostasis cannot be maintained and cell integrity may be impaired. The clinical consequences are recognized as occasional cause of morbidity and mortality. Although phosphate repletion has not been routinely recommended in the treatment of DKA, physicians should be aware of these clinical conditions and phosphate repletion in such situations should be considered.

Introduction

The phosphorus-depletion syndrome has been known to veterinary surgeons for many decades. In the 1960s, the phosphorus-depletion syndrome was first described in Man by Bloom and Flinchum,Citation1 who also reported a case of muscle weakness and osteomalacia in a patient with excessive ingestion of nonabsorbable antacids containing magnesium–aluminum hydroxides, which limit gastrointestinal absorption of phosphorus. Lotz et alCitation2 presented the effects of experimental phosphorus depletion in three normal volunteers and in three patients with parathyroid dysfunction during prolonged treatment with antacids. They observed a syndrome with hypophosphatemia, increased absorption of skeletal calcium and phosphorus, and clinical symptoms such as debilitation, anorexia, weakness, and bone pain. These reports were followed by more extensive research and reviews.Citation3Citation5

Recently, we have presented the evidence of the occurrence of a paradoxical imbalance in phosphate metabolism from the early onset of diabetes mellitus and have indicated that this imbalance may lead to a reduction of high energy phosphates and tissue hypoxia. These changes take place in cells and tissues in which the entry of glucose is not controlled by insulin and occur particularly in poorly regulated, though ambulatory diabetic patients in whom long-term vascular complications are more likely.Citation6,Citation7

In this article, we review the evidence suggesting the role of cellular phosphorus depletion and hypophosphatemia in the development of acute, occasionally life-threatening complications in hospitalized patients during treatment of diabetic ketoacidosis (DKA). The review is based on a search primarily using Medline (PubMed) and secondarily Embase, as well as information from reference lists.

Inorganic phosphate and ketoacidosis

DKA is associated with various degrees of intracellular phosphate depletion, partially because of a shift of phosphorus from the intracellular to the extracellular compartments and because of prolonged and excessive hyperphosphaturia.Citation6 During DKA, the plasma inorganic phosphate (Pi) may be normal or even elevated despite intracellular phosphate depletion. Initial treatment with intravenous fluid and insulin allows sudden entry of plasma glucose and phosphate into the insulin-sensitive tissues for cellular phosphorylation, and plasma Pi may be drastically decreased. Riley et alCitation8 demonstrated that insulin-induced hypophosphatemia is dose dependent and significant hypophosphatemia may occur within 30 minutes following administration of insulin. In the clinical situation, “refeeding” hypophosphatemia is usually first recognized at the second day of treatment and may last for a week depending on the degree of intracellular phosphate depletion and the replacement rate of intravenous fluid and insulin. In contrast to plasma Pi, the degree of intracellular phosphate cannot be clinically determined on admission because this parameter depends on the preceding dietary intake of phosphorus, the duration of the ketotic state, and the presence of associated factors, such as stress, infections, and duration of insufficient insulin intake.

Cellular phosphate depletion and associated hypophosphatemia, if severe, may give rise to signs and symptoms from many organ systems and is recognized as a cause of morbidity and mortality in DKA. When insufficient phosphate and oxygen are available for adenosine triphosphate (ATP) synthesis, cell homeostasis cannot be maintained and may result in cell lyses.Citation9 Because randomized studies of patients with ketoacidosis on phosphate therapy did not affect the duration of DKA, dose of insulin required to the acidosis, abnormal muscle enzyme levels, glucose disappearance rate, or morbidity and mortality, phosphate therapy is not an essential part of the therapy for DKA in most patients.Citation10Citation13 However, although phosphate repletion is not recommended as an adjuvant in the treatment of DKA,Citation14 physicians should be aware of the clinical manifestations to ensure no delay in phosphate repletion in such situations.

Hematological manifestations

Phosphorus plays an important role in several aspect of cellular metabolism, including ATP synthesis, which is the source of energy for many cellular reactions, and red cell 2,3-diphosphoglycerate (2,3-DPG), which regulates the dissociation of oxygen from hemoglobin. Studies have shown low levels of 2,3-DPG and ATP in red blood cells and the fact that low levels of intraerythrocytic phosphate inhibit whereas high levels stimulate red cell glycolysis.Citation15Citation17 During DKA, the effect of increased hydrogen ions on the oxyhemoglobin dissociation curve (ODC) is balanced by the diminished 2,3-DPG. However, after correction of acidosis, the low 2,3-DPG level shifts the ODC markedly to the left with a corresponding decrease in the ODC P50 (oxygen tension at 50% oxygen saturation). In close correlation with plasma Pi concentration, it may take up to 1 week for 2,3-DPG to return to an approximately normal level, and the oxygen delivery to tissues will be impaired for the same period ().Citation18Citation20 P50 of ODC at in vivo pH in 10 consecutive cases of ketoacidosis following insulin administration correlated closely with plasma Pi (r = 0.80; P < 0.001) and red cell 2,3-DPG (r = 0.94; P < 0.001).Citation21 This deficient oxygen delivery influences all organs and tissues, although organs with high oxygen demand, such as the renal medulla, brain, retina, pancreas, and heart, may suffer the most.

Figure 1 Pattern of changes in plasma phosphate (Δ), 2,3-DPG (●), and P50 at in vivo pH on the oxyhemoglobin dissociation curve (○) in a case of diabetic ketoacidosis.

Abbreviations: 2,3-DPG, 2,3-diphosphoglycerate; Hb, hemoglobin.

Figure 1 Pattern of changes in plasma phosphate (Δ), 2,3-DPG (●), and P50 at in vivo pH on the oxyhemoglobin dissociation curve (○) in a case of diabetic ketoacidosis. Abbreviations: 2,3-DPG, 2,3-diphosphoglycerate; Hb, hemoglobin.

When red cell ATP is significantly decreased, the erythrocyte membrane becomes rigid, and such erythrocytes may be trapped in the spleen leading to hemolytic anemia.Citation22 When ATP levels in the leukocytes are significantly decreased, their phagocytic, chemotactic, and bactericidal activities are reduced.Citation23

Neurological manifestations

Encephalopathy, confusion, seizures, hallucinations, and coma are the clinical signs that may develop during prolonged, severe hypophosphatemia following treatment of DKA. When verified, these symptoms should be promptly treated with intravenous phosphate, which often result in dramatic recovery.Citation24Citation27

Muscular manifestations

Muscular weakness is a common symptom, and myopathy, even in its more severe form as rhabdomyolysis, may occur.Citation28,Citation29 Among 12 consecutively admitted ketoacidotic patients, we found five with asymptomatic hypermyoglobulinemia and elevated creatine kinase isoenzyme MM, characteristic of rhabdomyolysis.Citation29 Patients with DKA are invariably dehydrated – often severely – and restoration of fluid and electrolytes is of first priority. In DKA, a remarkable small extraction of oxygen takes place through muscular and cutaneous tissues.Citation18,Citation30 Patients with DKA, in addition to dehydration, may also be in a preshock situation, which leads to a considerably increased release of catecholamine, mainly noradrenalin,Citation31 and a redistribution of microcirculatory flow. The arterioles in the cutaneous and splanchnic areas may be constricted, and blood flow will be shunted through biomicroscopically observable arteriolar–venular communications (thoroughfare channels; vascular pattern-change II) whereby blood flow bypasses the nutritive capillaries.Citation32 The resulting ischemic hypoxia of glucose- and phosphate- starved muscle cells may lead to reduced ATP, resulting in membrane disruption and allowing myoglobin and creatine kinase isoenzyme MM to enter into the circulation.

Myocardial manifestations

Møller et alCitation33 presented two patients with severe DKA, who showed elevations of the biomarkers troponin T and creatine kinase MB and initial electrocardiographic changes compatible with myocardial infarction. However, all successive investigations including coronary arteriography were normal. The concentration of plasma Pi was not reported. Hypophosphatemia is known to be associated with low levels of cellular ATP and impairment of human myocardial performance.Citation34,Citation35

Pulmonary manifestations

Acute respiratory failure in DKA patients with severe hypophosphatemia has been reported, and normally good results have been reported with phosphate replacement.Citation36,Citation37

Renal manifestations

Dehydration, volume depletion, renal hypoperfusion, and decreased intracellular tubular phosphate content often occur. Therefore, signs of renal tubular cell damage, as indicated by increased urinary excretion of enzymes from the brush border membrane such as increased urinary excretion of β2-microglobulin, γ-glutamyltransferase, leucine aminopeptidase, and N-acetyl-β-d-glucosaminidase, are common. Cases of renal tubular acidosis have also been seen.Citation38Citation40 These tubular cell disturbances may occur despite normal glomerular function.

Gastrointestinal manifestations

Nonspecific hyperamylasemia and abdominal pain are frequent findings during and after treatment of DKA with significantly negative correlation with plasma Pi.Citation41Citation43 In a study of 12 patients with ketoacidosis, salivary, pancreatic isoamylases, and pancreas lipase were determined. Hyperamylasemia was present in six patients, of which, five showed simultaneous increases in all three specific pancreatic enzymes, and one had increased salivary isoamylases alone. In none of the patients, the clinical course or the time-concentration curves of pancreatic enzymes were consistent with acute pancreatitis.Citation43

Discussion

Despite the prevalence of hypophosphatemia, the aforementioned acute clinical consequences are not common. Some of the cited references are from the period prior to the advent of routine, low-dose insulin administration. However, as indicated, the early and severe hypophosphatemia associated with the recovery phase of DKA seems to be related to rapid uptake of glucose and Pi by the insulin-sensitive cells and tissues following the administration of insulin and correction of acidosis. In this situation, the insulin-insensitive cells may continue to be phosphate-starved and may suffer from affinity hypoxia with associated metabolic consequences. A flowchart indicating the most important factors leading to ATP deficiency in and during recovery from DKA is presented in . Acidosis induces low red cell 2,3-DPG because of inhibition of phosphofructokinase and dehydration. Through redistribution of regional microcirculation and shunt flow, ischemic hypoxia may develop, which can be curtailed by rehydration.

Figure 2 A flowchart indicating the most important factors leading to ATP deficiency in and during recovery from diabetic ketoacidosis.

Abbreviations: ATP, adenosine triphosphate; ODC, oxyhemoglobin dissociation curve; 2,3-DPG, 2,3-diphosphoglycerate.

Figure 2 A flowchart indicating the most important factors leading to ATP deficiency in and during recovery from diabetic ketoacidosis. Abbreviations: ATP, adenosine triphosphate; ODC, oxyhemoglobin dissociation curve; 2,3-DPG, 2,3-diphosphoglycerate.

As insulin begins to normalize glucose metabolism in the insulin-sensitive tissues, phosphorus enters into the cells and marked hypophosphatemia may develop. Hypophosphatemia slows the abolishment of affinity hypoxia (). The two important elements, phosphorus and oxygen, for optimal ATP synthesis may thereby be limiting factors. Following the initial treatment of DKA, the cells of many organs and tissues may release enzymes, most likely because of this inhibition of energy metabolism. The resulting ATP depletion may lead to fluxes of Na+, K+, and Cl according to their gradients across the cellular membranes and with swelling of cells. Subsequently, Ca2+ may leak into the cells, activating phospholipases and the formation of eicosanoids, affecting the cytoskeleton, and initiating oxidant formation. The precise “point of no return” is unknown, but uncontrolled Ca2+ activity in the cell probably has an important role in initiating irreversible cell damage.Citation44

Diabetic patients with clinical symptoms of phosphate depletion and severe hypophosphatemia (<1.0 mg/dL); (tetany, seizures, prolonged unconsciousness, rhabdomyolysis, respiratory failure, and ventricular tachycardia) and those with one or more defective oxygen transport mechanisms (severe anemia, chronic obstructive pulmonary disease, and congestive heart failure) should be repleted with phosphate. The symptoms and signs of phosphate depletion can vary, are nonspecific, and are usually seen in patients with multiple problems. This makes it difficult to identify phosphate depletion as the cause of the clinical manifestations.Citation45 The response to phosphorus repletion with solutions of Pi is usually effective and safe.Citation46 The organic phosphate, fructose 1,6-diphosphate (FDP), a key intermediate in glycolysis and the product of the major regulatory enzyme in the pathway (phosphofructokinase), has been suggested as an alternative. FDP acts as human bioenergy and can transport phosphorous into cells and, in a single report, FDP was shown to be more effective and safe than plasma Pi in restoring red cell 2,3-DPG in patients.Citation47 Further studies on this subject are clearly needed before any conclusion can be reached.

Disclosure

The authors report no conflicts of interest in this work.

References

  • Bloom WL Flinchum D Osteomalacia with pseudofractures caused by ingestion of aluminum hydroxide JAMA 1960 174 10 1327 1330
  • Lotz M Zisman E Bartter FC Evidence for a phosphorus-depletion syndrome in man N Engl J Med 1968 278 8 409 415 5636663
  • Knochel JP The pathophysiology and clinical characteristics of severe hypophosphatemia Arch Intern Med 1977 137 2 203 220 836118
  • Kreusser W Ritz E Boland R Phosphat-depletion Klin Wochenschr 1980 58 1 1 15 6768928
  • Amanzadeh J Reilly RF Hypophosphatemia: an evidence-based approach to its clinical consequences and management Nat Clin Pract Nephrol 2006 2 3 136 148 16932412
  • Ditzel J Lervang HH Disturbance of inorganic phosphate metabolism in diabetes mellitus: temporary therapeutic intervention trials Diabetes Metab Syndr Obes 2009 2 173 177
  • Ditzel J Lervang HH Disturbance of inorganic phosphate metabolism in diabetes mellitus: its impact on the development of diabetic late complications Curr Diabetes Rev 2010 6 5 323 333 20701584
  • Riley MS Shade DS Eaton RP Effects of insulin injection on plasma phosphate in diabetic patients Metabolism 1979 28 3 191 194 105228
  • Farber E ATP and cell integrity Fed Proc 1973 32 4 1534 1539 4573768
  • Keller U Berger W Prevention of hypophosphatemia by phosphate infusion during treatment of diabetic ketoacidosis and hyperosmolar coma Diabetes 1980 29 2 87 94 6766411
  • Wilson HK Keuer SP Scott Lea A Boyd AEIII Eknoyan G Phosphate therapy in diabetic ketoacidosis Arch Intern Med 1982 142 3 517 520 6802095
  • Becker D Brown DE Steranka BH Drash AL Phosphate replacement during treatment of diabetic ketosis Am J Dis Child 1983 137 3 241 246 6401918
  • Fisher JN Kitabchi AE A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis J Clin Endocrinol Metab 1983 57 1 177 180 6406531
  • Wolfdorf J Glasser N Sperling MA Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from American Diabetes Association Diabetes Care 2006 29 5 1150 1159 16644656
  • Travis SF Sugerman HJ Ruberg R Alterations of red-cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatemia in patients receiving intravenous hyperalimentation N Engl J Med 1971 285 14 763 768 4998555
  • Sheldon GF Grzyb S Phosphate depletion and repletion: relation to parenteral nutrition and oxygen transport Ann Surg 1975 182 6 683 689 811182
  • Lichtman MA Miller DR Erythrocyte glycolysis, 2,3-diphosphoglycerate and adenosine triphosphate concentration in uremic subjects: relationship to extracellular phosphate concentration J Lab Clin Med 1970 76 2 267 279 5434006
  • Bellingham AJ Detter JC Lenfant C The role of hemoglobin affinity for oxygen and red cell 2,3-DPG in the management of diabetic ketoacidosis Trans Assoc Am Physicians 1970 83 113 120 4994298
  • Alberti KGMM Emerson PM Darley JH Hochaday TD 2,3-diphosphoglycerate and tissue oxygenation in uncontrolled diabetes Lancet 1972 2 7774 391 395 4115219
  • Ditzel J Standl E The oxygen transport system of red blood cells during diabetic ketoacidosis and recovery Diabetologia 1975 11 4 255 260 1319
  • Ditzel J Problem of tissue oxygenation in diabetes as related to development of diabetic retinopathy Mausoft FA Eye and Systemic Disease Saint Louis, Toronto, London C.V. Mosby Company 1980 179 186
  • Shilo P Werner D Hershko C Acute hemolytic anemia caused by severe hypophosphatemia in diabetic ketoacidosis Acta Haematol 1985 73 1 55 57 3923771
  • Chinn RY Diamond RD Generation of chemotactic factors by Rhizopus aryzae in the presence or absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis Infect Immun 1982 38 2 1123 1129 6818145
  • Franks M Berris RF Kaplan NO Myers GB Metabolic studies in diabetic acidosis; Part II: the effect of the administration of sodium phosphate Arch Intern Med 1948 81 1 42 55
  • Ditzel J Effect of plasma inorganic phosphate on tissue oxygenation during recovery from diabetic ketoacidosis Adv Exp Med Biol 1973 37A 163 172 4220244
  • Megarbane B Guerrier G Blanche A Meas T Guillanestau PJ Baud FJ A possible hypophosphatemia-induced, life-threatening encephalopathy in ketoacidosis: a case report Am J Med Sci 2007 333 6 384 386 17570993
  • de Oliveira Iglesias SB Pons Leite H de Carvalho WB Hypophosphatemia-induced seizure in a child with diabetic ketoacidosis Pediatr Emerg Care 2009 25 12 859 861 20016359
  • Singhal PC Kumar A Desroches L Gibbons N Mattana J Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia Am J Med 1992 92 5 458 464 1580292
  • Møller-Petersen J Thorgaard Andersen P Hjørne N Ditzel J Non-traumatic rhabdomyolysis during diabetic ketoacidosis Diabetologia 1986 29 4 229 234 3086167
  • Ditzel J Standl E The problem of tissue oxygenation in diabetes mellitus; Part II: evidence of disordered oxygen release from the erythrocytes in diabetics in various conditions of metabolic control Acta Med Scand 1975 197 Suppl 578 S49 S58
  • Christensen NJ Plasma noradrenaline and adrenaline measured by isotope-derivative assay. A review with special reference to diabetes mellitus Dan Med Bull 1979 26 1 17 36 367719
  • Ditzel J Sargeant L Hadley WB The relationship of abnormal vascular responses to retinopathy and nephropathy in diabetics Arch Intern Med 1958 101 5 912 920
  • Møller N Foss AC Gravholt CH Mortensen UM Poulsen SH Mogensen CE Myocardial injury with biomarker elevation in diabetic ketoacidosis J Diabet Complications 2005 19 6 361 363
  • O’Connor LR Wheeler WS Bethune JE Effect of hypophosphatemia on myocardial performance in man N Engl J Med 1977 297 17 901 903 904668
  • Darsee JR Nutter DO Reversible severe congestive cardiomyopathy in three cases of hypophosphatemia Ann Intern Med 1978 89 6 867 870 363007
  • Hasselstrøm L Wimberley PD Nielsen VG Hypophosphatemia and acute respiratory failure in a diabetic patient Intensive Care Med 1986 12 6 429 431 3098815
  • Liu PY Jeng CY Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure J Chin Med Assoc 2004 67 7 355 359 15510933
  • Miltenyi M Körner A Tulassay T Szabo A Tubular dysfunction in type I diabetes mellitus Arch Dis Child 1985 60 10 929 931 3933437
  • Miltenyi M Szabo A Tulassay T Körner A Kenesei E Dobos M Reduced glomerular filtration and elevated urinary protein excretion in diabetic ketoacidosis Acta Paediatr Scand 1990 79 4 444 447 2112297
  • Guammarco R Goldstein MB Halperin ML Stinebaugh BJ Renal tubular acidosis during therapy for diabetic ketoacidosis Can Med Assoc J 1975 112 4 463 466 234290
  • Yadav D Nair S Norkus EP Pitchumoni CS Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities Am J Gastroenterol 2000 95 11 3123 3128 11095328
  • Kjærgaard JJ Salling N Magid E Ditzel J Serum amylase during recovery from diabetic ketoacidosis Diabete Metab (Paris) 1984 10 1 25 30
  • Møller-Petersen J Andersen PT Hjørne N Ditzel J Hyperamylasemia, specific pancreatic enzymes, and hypoxanthine during recovery from diabetic ketoacidosis Clin Chem 1985 31 12 2001 2004 2415270
  • Kristensen SR Mechanisms of cell damage and enzyme release Dan Med Bull 1994 41 4 423 433 7813251
  • Berner YN Shike M Consequences of phosphate imbalance Annu Rev Nutr 1988 8 121 148 3060161
  • Vannatta JB Whang R Papper S Efficacy of intravenous phosphorus therapy in the severely hypophosphatemic patient Arch Intern Med 1981 141 7 885 887 7235807
  • Iapichino G Radrizzani D Solca M Restoration of blood 2,3-diphosphoglycerate levels in multitransfused patients: effect of organic and inorganic phosphate Int Surg 1984 69 2 113 116 6500874